On Friday, AN2 Therapeutics Inc (NASDAQ: ANTX) was 21.90% up from the session before settling in for the closing price of $1.37. A 52-week range for ANTX has been $0.87 – $22.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 37.08%. With a float of $21.16 million, this company’s outstanding shares have now reached $29.74 million.
Let’s look at the performance matrix of the company that is accounted for 41 employees. In terms of profitability, gross margin is 50.0%, operating margin of -83756.25%, and the pretax margin is -75871.25%.
AN2 Therapeutics Inc (ANTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward AN2 Therapeutics Inc stocks. The insider ownership of AN2 Therapeutics Inc is 29.18%, while institutional ownership is 40.02%. The most recent insider transaction that took place on Nov 27 ’24, was worth 70,840. In this transaction Director of this company bought 50,000 shares at a rate of $1.42, taking the stock ownership to the 622,573 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Director bought 25,000 for $1.39, making the entire transaction worth $34,845. This insider now owns 597,573 shares in total.
AN2 Therapeutics Inc (ANTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 37.08% per share during the next fiscal year.
AN2 Therapeutics Inc (NASDAQ: ANTX) Trading Performance Indicators
You can see what AN2 Therapeutics Inc (ANTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics Inc (NASDAQ: ANTX) saw its 5-day average volume 0.79 million, a positive change from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 87.39%. Additionally, its Average True Range was 0.10.
During the past 100 days, AN2 Therapeutics Inc’s (ANTX) raw stochastic average was set at 36.36%, which indicates a significant decrease from 99.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 123.74% in the past 14 days, which was lower than the 162.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1045, while its 200-day Moving Average is $2.0139. Nevertheless, the first resistance level for the watch stands at $1.7400 in the near term. At $1.8100, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.9450. If the price goes on to break the first support level at $1.5350, it is likely to go to the next support level at $1.4000. The third support level lies at $1.3300 if the price breaches the second support level.
AN2 Therapeutics Inc (NASDAQ: ANTX) Key Stats
There are 29,879K outstanding shares of the company, which has a market capitalization of 60.83 million. As of now, sales total 0 K while income totals -64,730 K. Its latest quarter income was 0 K while its last quarter net income were -12,750 K.
